bioMerieux(GB:0RUG)
€90.55-1.35 (-1.47%)
GB:0RUG
bioMerieux financials statements
€90.55
At close:-1.35 (-1.47%)
bioMerieux (0RUG) Ratios
3 Followers
bioMerieux Ratios
GB:0RUG's free cash flow for Q2 2026 was €297.30M. For the 2026 fiscal year, GB:0RUG's free cash flow was decreased by €-139.50M and operating cash flow was €436.80M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.39 | 2.20 | 2.03 | 1.96 | 2.29 |
| Quick Ratio | 1.47 | 1.29 | 1.19 | 1.28 | 1.61 |
| Cash Ratio | 0.54 | 0.40 | 0.32 | 0.49 | 0.84 |
| Solvency Ratio | 0.57 | 0.47 | 0.41 | 0.46 | 0.57 |
| Operating Cash Flow Ratio | 0.74 | 0.59 | 0.41 | 0.42 | 0.86 |
| Short-Term Operating Cash Flow Coverage | 7.94 | 5.98 | 3.27 | 2.95 | 11.01 |
| Net Current Asset Value | € 1.07B | € 942.10M | € 698.20M | € 673.00M | € 743.20M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.08 | 0.09 | 0.10 | 0.10 | 0.10 |
| Debt-to-Equity Ratio | 0.11 | 0.12 | 0.14 | 0.14 | 0.15 |
| Debt-to-Capital Ratio | 0.10 | 0.10 | 0.12 | 0.12 | 0.13 |
| Long-Term Debt-to-Capital Ratio | 0.05 | 0.05 | 0.06 | 0.06 | 0.08 |
| Financial Leverage Ratio | 1.36 | 1.37 | 1.40 | 1.44 | 1.48 |
| Debt Service Coverage Ratio | 7.57 | 5.82 | 4.18 | 4.26 | 9.86 |
| Interest Coverage Ratio | 35.52 | 36.80 | 99.80 | 136.54 | 84.40 |
| Debt to Market Cap | 0.02 | 0.03 | 0.03 | 0.03 | 0.02 |
| Interest Debt Per Share | 4.05 | 4.30 | 4.43 | 4.32 | 3.99 |
| Net Debt to EBITDA | -0.11 | 0.05 | 0.24 | -0.06 | -0.35 |
| Profitability Margins | |||||
| Gross Profit Margin | 52.63% | 55.66% | 55.99% | 54.64% | 58.33% |
| EBIT Margin | 13.79% | 14.96% | 12.03% | 15.44% | 22.43% |
| EBITDA Margin | 24.56% | 22.55% | 19.08% | 22.62% | 28.96% |
| Operating Profit Margin | 13.79% | 14.79% | 11.95% | 15.60% | 22.75% |
| Pretax Profit Margin | 12.91% | 14.56% | 11.91% | 15.33% | 22.16% |
| Net Profit Margin | 9.77% | 10.86% | 9.73% | 12.60% | 17.80% |
| Continuous Operations Profit Margin | 9.75% | 10.68% | 8.79% | 12.27% | 17.74% |
| Net Income Per EBT | 75.64% | 74.61% | 81.74% | 82.22% | 80.33% |
| EBT Per EBIT | 93.64% | 98.39% | 99.64% | 98.29% | 97.43% |
| Return on Assets (ROA) | 7.13% | 7.49% | 6.80% | 8.72% | 13.05% |
| Return on Equity (ROE) | 9.69% | 10.28% | 9.53% | 12.55% | 19.31% |
| Return on Capital Employed (ROCE) | 12.44% | 12.70% | 10.53% | 13.80% | 21.05% |
| Return on Invested Capital (ROIC) | 9.13% | 9.04% | 7.48% | 10.56% | 16.40% |
| Return on Tangible Assets | 8.94% | 9.50% | 8.87% | 15.41% | 21.06% |
| Earnings Yield | 3.06% | 3.55% | 3.01% | 3.92% | 4.07% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.29 | 4.64 | 4.25 | 4.15 | 4.76 |
| Payables Turnover | 7.36 | 6.48 | 6.10 | 6.04 | 5.87 |
| Inventory Turnover | 1.98 | 1.70 | 1.78 | 2.12 | 2.17 |
| Fixed Asset Turnover | 2.46 | 2.35 | 2.44 | 2.62 | 2.76 |
| Asset Turnover | 0.73 | 0.69 | 0.70 | 0.69 | 0.73 |
| Working Capital Turnover Ratio | 2.86 | 3.20 | 3.34 | 3.10 | 3.43 |
| Cash Conversion Cycle | 220.05 | 236.87 | 231.16 | 199.66 | 182.69 |
| Days of Sales Outstanding | 85.04 | 78.65 | 85.97 | 87.99 | 76.65 |
| Days of Inventory Outstanding | 184.64 | 214.56 | 205.02 | 172.07 | 168.18 |
| Days of Payables Outstanding | 49.62 | 56.34 | 59.83 | 60.40 | 62.14 |
| Operating Cycle | 269.68 | 293.21 | 290.99 | 260.06 | 244.83 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 6.68 | 5.67 | 3.77 | 4.03 | 6.97 |
| Free Cash Flow Per Share | 3.84 | 2.73 | 0.91 | 1.60 | 4.52 |
| Dividend Paid and CapEx Coverage Ratio | 1.79 | 1.50 | 1.02 | 1.22 | 2.27 |
| Capital Expenditure Coverage Ratio | 2.35 | 1.93 | 1.32 | 1.66 | 2.84 |
| Operating Cash Flow Coverage Ratio | 1.71 | 1.36 | 0.86 | 0.94 | 1.78 |
| Operating Cash Flow to Sales Ratio | 0.19 | 0.17 | 0.12 | 0.13 | 0.24 |
| Free Cash Flow Yield | 3.48% | 2.64% | 0.90% | 1.63% | 3.62% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 32.73 | 28.20 | 33.21 | 25.53 | 24.57 |
| Price-to-Sales (P/S) Ratio | 3.20 | 3.06 | 3.23 | 3.22 | 4.38 |
| Price-to-Book (P/B) Ratio | 3.17 | 2.90 | 3.17 | 3.20 | 4.75 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 28.72 | 37.91 | 110.89 | 61.30 | 27.63 |
| Price-to-Operating Cash Flow Ratio | 16.50 | 18.27 | 26.66 | 24.31 | 17.91 |
| Price-to-Earnings Growth (PEG) Ratio | -4.00 | 1.34 | -1.57 | -1.05 | 0.51 |
| Enterprise Value Multiple | 12.91 | 13.63 | 17.17 | 14.17 | 14.76 |
| Enterprise Value | 12.90B | 12.23B | 12.04B | 11.50B | 14.43B |
| EV to EBITDA | 12.91 | 13.63 | 17.17 | 14.17 | 14.76 |
| EV to Sales | 3.17 | 3.07 | 3.28 | 3.20 | 4.27 |
| EV to Free Cash Flow | 28.48 | 38.04 | 112.44 | 61.05 | 26.99 |
| EV to Operating Cash Flow | 16.37 | 18.33 | 27.04 | 24.21 | 17.50 |
| Tangible Book Value Per Share | 25.24 | 25.38 | 21.39 | 11.81 | 11.95 |
| Shareholders’ Equity Per Share | 34.78 | 35.71 | 31.78 | 30.56 | 26.32 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.25 | 0.27 | 0.26 | 0.20 | 0.20 |
| Revenue Per Share | 34.50 | 33.80 | 31.13 | 30.43 | 28.55 |
| Net Income Per Share | 3.37 | 3.67 | 3.03 | 3.84 | 5.08 |
| Tax Burden | 0.76 | 0.75 | 0.82 | 0.82 | 0.80 |
| Interest Burden | 0.94 | 0.97 | 0.99 | 0.99 | 0.99 |
| Research & Development to Revenue | 0.12 | 0.12 | 0.13 | 0.12 | 0.11 |
| SG&A to Revenue | 0.27 | 0.28 | 0.08 | 0.07 | 0.07 |
| Stock-Based Compensation to Revenue | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 |
| Income Quality | 1.98 | 1.57 | 1.25 | 1.05 | 1.37 |
Currency in EUR

